P2–412: MPC–7869 (R–flurbiprofen), a selective Aβ42–lowering agent, delays time to clinically significant psychiatric events in Alzheimer's disease (AD): Analysis from a 12–month phase 2 trial | Zendy

Mintzer Jacobo E. | Zendy; Wilcock Gordon K. | Zendy; Black Sandra E. | Zendy; Zavitz Kenton H. | Zendy; Hendrix Suzanne B. | Zendy

Premium

P2–412: MPC–7869 (R–flurbiprofen), a selective Aβ42–lowering agent, delays time to clinically significant psychiatric events in Alzheimer's disease (AD): Analysis from a 12–month phase 2 trial

Author(s) -

Mintzer Jacobo E.,

Wilcock Gordon K.,

Black Sandra E.,

Zavitz Kenton H.,

Hendrix Suzanne B.

Publication year - 2006

Publication title -

alzheimer's and dementia

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.713

H-Index - 118

eISSN - 1552-5279

pISSN - 1552-5260

DOI - 10.1016/j.jalz.2006.05.1253

Subject(s) - placebo , adverse effect , medicine , dosing , exploratory analysis , donepezil , disease , psychiatry , dementia , pathology , alternative medicine , computer science , data science

A 42-LOWERING AGENT, DELAYS TIME TO CLINICALLY SIGNIFICANT PSYCHIATRIC EVENTS IN ALZHEIMER’S DISEASE (AD): ANALYSIS FROM A 12-MONTH PHASE 2 TRIAL Jacobo E. Mintzer, Gordon K. Wilcock, Sandra E. Black, Kenton H. Zavitz, Suzanne B. Hendrix, MPC-7869 Phase 2 Study Investigators, Department of Psychiatry, Medical University of South Carolina, Charleston, SC, USA; University of Bristol, Bristol, United Kingdom; Sunnybrook & Women’s, University of Toronto, Toronto, ON, Canada; Myriad Pharmaceuticals, Salt Lake City, UT, USA. Contact e-mail: kzavitz@myriad.com

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research